Perhaps not surprisingly, a Phase III study has shown that Zytiga extends life by 4.7 months on average, if taken before chemo.
A second trial, perhaps even more significantly, has shown that Zytiga significantly extends overall survival for men with very aggressive prostate cancers (with cancers with ERG mutations) by an average of 17.4 months.
The suggestion is to do genetic tests looking for the ERG mutations in patients with aggressive disease, and prioritize treatment with Zytiga for those with the mutations.
www.icr.ac.uk/news-archive/two-major-studies-strengthen-case-for-prostate-cancer-drug-before-chemotherapyAs a number of oncologists have written, it seems that medical science is making slow and steady gains in figuring out the optimal ways to use the tools we've got.
Arthur